TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25370504
Drug: Hybrid online
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid online training module for panic disorder (PD) based on cognitive behavioral therapy, consisting of six modules over six weeks
Study: 17365735
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch 63 mg/day
Study: 15483079
Drug: Anastrozole (aromatase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (aromatase inhibitor)
Study: 9793699
Drug: Zolmitriptan 2.5
Normalized name: zolmitriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 2.5 mg + Diazepam 10 mg
Study: 9793699
Drug: Zolmitriptan 5
Normalized name: zolmitriptan 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 5 mg + Diazepam 10 mg
Study: 8561268
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine alone
Study: 8561268
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine in combination with pefloxacin
Study: 8561268
Drug: Intravenous quinine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous quinine alone or in combination with pefloxacin
Study: 2523210
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of amoxycillin/clavulanic acid (1.2 g Augmentin) at induction of anaesthesia (n = 328)
Study: 2523210
Drug: Subcutaneous infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infiltration of amoxycillin/clavulanic acid (1.2 g Augmentin) along the line of the proposed incision (n = 296)
Study: 31023758
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of metformin daily
Study: 25482305
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 500 mg of naproxen and 20 mg of esomeprazole (test formulation)
Study: 25482305
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 500 mg of naproxen and 20 mg of esomeprazole (reference formulation)
Study: 16755394
Drug: Diagnosis and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnosis and treatment related to depression severity
Study: 12752138
Drug: Narrow-band UVB
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-band UVB (311 nm) + calcitriol (twice daily)
Study: 12752138
Drug: Narrow-band UVB
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-band UVB (311 nm) + dithranol (once daily)
Study: 10863060
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RTH) at a dose of 55 Gy/20 fractions/4 weeks
Study: 10863060
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RTH) at a dose of 64 Gy/32 fractions/6.5 weeks
Study: 10863060
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RTH)
Study: 9197430
Drug: gallopamil 150
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallopamil 150 mg/day
Study: 9197430
Drug: gallopamil 50
Normalized name: gallopamil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallopamil 50 mg t.i.d. for 28 days
Study: 20977356
Drug: n-acetyl-L-carnitine
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-acetyl-L-carnitine
Study: 11812667
Drug: Metoprolol 50-100
Normalized name: hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol 50-100 mg b.i.d.
Study: 11812667
Drug: Xamoterol 100-200
Normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol 100-200 mg b.i.d.
Study: 31364979
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg
Study: 7722712
Drug: High energy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy, high protein supplement (Atole)
Study: 7722712
Drug: Low energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low energy supplement with no protein (Fresco)
Study: 1585511
Drug: M-VAC chemotherapy
Normalized name: M-2698
DrugBank: M-2698 (DB15431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-VAC chemotherapy
Study: 2201047
Drug: Immunological agents
Normalized name: IMMUNOLOGICAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunological agents
Study: 2201047
Drug: New agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: New agents or regimens with intensive schedule
Study: 24389434
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg daily plus pemetrexed 500 mg/m2 intravenously every 3 weeks
Study: 24389434
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 intravenously every 3 weeks plus pemetrexed 500 mg/m2
Study: 20810005
Drug: Exposure treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure treatments (B-ERP and P-ERP)
Study: 18235425
Drug: Single nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single nasal dose of testosterone; administered in a double-blind, placebo-controlled, crossover manner.
Study: 18235425
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group); administered in a double-blind, placebo-controlled, crossover manner.
Study: 18930646
Drug: Salbutamol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (400 mcg)
Study: 23574529
Drug: Exenatide 5-μg
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide 5-μg twice daily
Study: 23574529
Drug: Exenatide 10-μg
Normalized name: exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide 10-μg twice daily
Study: 22051148
Drug: TAK-875 400
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 400 mg
Study: 23086138
Drug: TAK-875 100
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-875 100 mg
Study: 16457083
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO2), 45 minutes daily for 10 days
Study: 12859697
Drug: Ibandronate 20
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 20 mg/week
Study: 10849263
Drug: Interferon-alpha (IFN-α)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN-α) 3 or 5 million units (MU) three times weekly (t.i.w.) for 3 months, intensified to daily therapy for those with detectable HCV RNA at 3 months.
Study: 10849263
Drug: Interferon-alpha (IFN-α)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN-α) three times weekly (t.i.w.) for 3 months (control group).
Study: 8646959
Drug: Anterior sacral
Normalized name: Boswellia sacra whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior sacral roots stimulator implants
Study: 6401927
Drug: Norethindrone oral
Normalized name: norethindrone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethindrone oral contraceptive
Study: 6401927
Drug: Norgestrel oral
Normalized name: norgestrel Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestrel oral contraceptive
Study: 27799239
Drug: Complementary food
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary food supplements and dietary counselling
Study: 21703973
Drug: Topical budesonide
Normalized name: budesonide Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical budesonide mouthwash (3 mg/10 mL) applied for 5 or 10 minutes, 2 or 3 times daily
Study: 19622714
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg qd
Study: 19622714
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg qd
Study: 19622714
Drug: Glyburide 5
Normalized name: glyburide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide 5 mg
Study: 19622714
Drug: Alogliptin 25
Normalized name: alogliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin 25 mg qd with glyburide
Study: 15708173
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Cerivastatin + CoQ(10))
Study: 2690898
Drug: Oral cyclic
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclic estrogen/gestagen (n = 20)
Study: 2690898
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium (2000 mg elemental calcium per day) (n = 17)
Study: 28903941
Drug: Insulin provision
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin provision (IP) therapy
Study: 28314486
Drug: Insulin sensitizing
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin sensitizing (IS) therapy
Study: 25283522
Drug: Intravenous levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous levetiracetam 1,500 mg
Study: 25283522
Drug: Intravenous levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous levetiracetam 1,500 mg (single infusion)
Study: 25283522
Drug: Intravenous levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous levetiracetam 1,500 mg (repeated infusion)
Study: 16220495
Drug: Complete-case (CC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete-case (CC) method
Study: 15383187
Drug: Atorvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin treatment (dose titration to achieve LDL-C and non-HDL-C goals)
Study: 15383187
Drug: Atorvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin treatment (dose titration)
Study: 9868840
Drug: Vero-cell rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vero-cell rabies vaccine (PVRV, Verorab) according to the 2-1-1 schedule
Study: 9868840
Drug: Vero-cell rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vero-cell rabies vaccine (PVRV) plus equine rabies immunoglobulins (ERIG, 40 IU/kg body weight) according to the 2-1-1 schedule
Study: 9868840
Drug: Vero-cell rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vero-cell rabies vaccine (PVRV) plus human rabies immunoglobulins (HRIG, 20 IU/kg body weight) according to the 2-1-1 schedule
Study: 8091167
Drug: Omeprazole (OME)
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole (OME) 40 mg bid and Amoxicillin (AMOX) 750 mg tid for 10 days with N-acetylcysteine (NAC) 2 x 600 mg bid (d 21‐30)
Study: 8091167
Drug: Omeprazole (OME)
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole (OME) 40 mg bid and Amoxicillin (AMOX) 750 mg tid for 10 days without N-acetylcysteine (NAC)
Study: 1130178
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 (2,000 IU daily) for 3 months
Study: 18041485
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg zaleplon
Study: 21765069
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of IPTp-SP (n = 413)
Study: 21765069
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of IPTp-SP (n = 401)
Study: 19015207
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 200 mg plus methotrexate (MTX)
Study: 19015207
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 400 mg plus methotrexate (MTX)
Study: 16759926
Drug: 25 IU
Normalized name: Calcium/Vitamin D 200 MG-125 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 IU weekly increments of rFSH
Study: 16759926
Drug: 50 IU
Normalized name: Pegaspargase 750 IU/1 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 IU weekly increments of rFSH
Study: 15295244
Drug: Etomidate (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (up to 0.3 mg/kg, n = 7)
Study: 15295244
Drug: Etomidate (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (up to 0.4 mg/kg, n = 17)
Study: 15295244
Drug: Pentobarbital (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbital (up to 5 mg/kg, n = 33)
Study: 11699053
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (1,142.0 +/- 79.64 microg/d for at least 12 months)
Study: 30315901
Drug: Fingolimod (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod (0.5, 1.25, or 5 mg/day)
Study: 30315901
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or intramuscular interferon beta‐1a (IFNβ‐1a IM)
Study: 21318442
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine injection
Study: 18496062
Drug: Heparin flushes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin flushes (1:100 dilution)
Study: 12706129
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition enriched with glutamine (0.7 g kg(‐1)day(‐1))
Study: 10910450
Drug: Continued MMF
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued MMF treatment (2 g b.i.d.) in group A, n=22
Study: 10910450
Drug: Switching to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching to AZA treatment (1 mg/kg) in group B, n=26
Study: 22796985
Drug: Nicotine transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine transdermal patches
Study: 1569341
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg twice a day for 3 days
Study: 2866073
Drug: MK-208 5
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-208 5 mg
Study: 2866073
Drug: MK-208 10
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-208 10 mg
Study: 2866073
Drug: MK-208 20
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-208 20 mg
Study: 28952607
Drug: 180 mcg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mcg/day of vitamin K2 (menaquinone-7, MK-7)
Study: 30485516
Drug: Couples calls
Normalized name: Mosco Corn & Callus Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couples calls (CC)
Study: 22487663
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (morphine, ketorolac, and butylscopolammonium bromide)
Study: 22487663
Drug: Double therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double therapy (morphine and ketorolac)
Study: 11361192
Drug: Ibuprofen 2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 2,400 mg/day
Study: 7648766
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg (S)-ketamine
Study: 7648766
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg (S)-ketamine
Study: 7648766
Drug: 0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/kg (S)-ketamine (control)
Study: 1009523
Drug: Cyclophosphamide (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (1000 mg/m2 every 3 weeks) iv
Study: 1009523
Drug: Cyclophosphamide (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (700 mg/m2 every 3 weeks) iv plus CCNU (70 mg/m2 every 6 weeks) orally
Study: 1009523
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent (Cyclophosphamide)
Study: 19291601
Drug: 64-slice CT
Normalized name: Sklice
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 64-slice CT with 80 cc CM at 5 cc/sec followed by a 50 cc saline chaser bolus containing 20% contrast media
Study: 17290009
Drug: L-NMMA (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (low dose)
Study: 17290009
Drug: L-NMMA (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (high dose)
Study: 9105060
Drug: ONO‐1078 (pranlukast),
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO‐1078 (pranlukast), 450 mg twice daily
Study: 28631682
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy combined with homeovox
Study: 26508659
Drug: Adenosine treatment
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine treatment for 6 months
Study: 24594076
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 50-100mg daily for 2 days
Study: 19388861
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between acupuncture and sham treatment
Study: 15126928
Drug: Immediate antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antihypertensive treatment (nitrendipine 10-40 mg daily, possibly with enalapril 5-20 mg daily, hydrochlorothiazide 12.5-25 mg daily)
Study: 15126928
Drug: Delayed antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antihypertensive treatment (placebo)
Study: 15126928
Drug: Immediate antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antihypertensive treatment in diabetic patients (n=492)
Study: 2197535
Drug: 8 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g/d cotrimoxazole (TMP/SMX) i.v.
Study: 2197535
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg aerosolized pentamidine
Study: 347887
Drug: L-tryptophan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (6 g daily) and ECT
Study: 26420886
Drug: IVIG (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (0.4 g/kg 10% IVIG every 2 weeks for a total of 5 infusions, 2 g/kg total dose)
Study: 25529292
Drug: BCG vaccine
Normalized name: BCG Vaccine
DrugBank: BCG vaccine (DB12768)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG vaccine strain, LTBI, HIV infection, asymptomatic malaria, growth z-scores, childhood anthelminthic treatment, maternal BCG scar
Study: 21073372
Drug: Irsogladine 4
Normalized name: irsogladine
DrugBank: Irsogladine (DB13056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irsogladine 4 mg/day
Study: 15116294
Drug: Levofloxacin administered
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin administered as an infusion of 500 mg/h for 1.5 h (total dose, 750 mg) with additional drugs for specific pathogens (ceftazidime or piperacillin/tazobactam for P. aeruginosa and vancomycin for methicillin-resistant S. aureus).
Study: 8426211
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial therapy with floxuridine, mitomycin, and carmustine (FMB)
Study: 8426211
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial therapy with floxuridine alone (F)
Study: 6150140
Drug: Intravenous gammaglobulin
Normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gammaglobulin prepared by Cohn fractionation of pooled plasma
Study: 24577097
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day of phosphatidylserine enriched with docosahexaenoic acid (PS-DHA)
Study: 22337277
Drug: Correction group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correction group (received infusion with fresh-frozen plasma and/or platelets)
Study: 19624554
Drug: Desloratadine (DL)
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine (DL) 5 mg once daily
Study: 16458655
Drug: Prenatal supplements
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal supplements with 30 mg of iron as ferrous sulfate (n = 218 women)
Study: 16458655
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg of iron (control group, n = 211 women)
Study: 8889421
Drug: suxamethonium (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium (1 mg kg‐1)
Study: 8889421
Drug: saline (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline (0.02 mL kg‐1)
Study: 6435961
Drug: L-Lysine monohydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Lysine monohydrochloride 1,248 mg/day
Study: 6435961
Drug: L-Lysine monohydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Lysine monohydrochloride 624 mg/day
Study: 6435961
Drug: L-Lysine monohydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Lysine monohydrochloride (both dosages)
Study: 31009578
Drug: Waiting-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list control (6-month delay in treatment)
Study: 26117247
Drug: Integrated Treatment
Normalized name: Bag Spike + Integrated Clave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Treatment Adherence Program